Cancer Drug Margins Capped at 30%: SC Hearing
Why in News?
- On 12 October 2026, the Centre told the Supreme Court that it has decided to cap the trade margin on anti-cancer drugs at 30 per cent of the maximum retail price.
- The government expects patients to save about Rs 2,500 crore a year. It used its extraordinary powers under Paragraph 19 of the Drugs (Prices Control) Order, 2013.
- The National Pharmaceutical Pricing Authority approved the proposal in principle at its 151st meeting on 8 October 2026. The list of covered medicines is still pending.
- A bench of Justices Vikram Nath and Sandeep Mehta said "There is hardly anything to be happy about" and asked why margins on other medicines cannot also be capped.
- The Court gave the government time to work out how to cap medicine prices and listed the matter for 27 October 2026.
Key Terminologies
- Trade margin
- The difference between the price at which a manufacturer sells to the trade and the maximum retail price. It is the margin kept by wholesalers and retailers.
- Maximum retail price
- The highest price at which a drug can be sold to a consumer. The cap of 30 per cent applies to this price.
- Non-scheduled drugs
- Medicines that are not listed in Schedule I of the Drugs (Prices Control) Order, 2013. Their prices are not fixed directly, though Paragraph 19 lets the government control them in the public interest.
- Paragraph 19
- The extraordinary-powers provision of the Drugs (Prices Control) Order, 2013. The government invoked it for the 2019 and 2026 cancer drug measures.
Key Issues
- Steep Markups: The Authority's market data found that non-scheduled anti-cancer medicines carry an average mark-up of about 170 per cent, and 700 per cent or more in some cases. The data came from Pharmarack, per its meeting minutes.
- Large Market: India's anti-cancer market has about 225 drugs and 500 formulations, with annual turnover of roughly Rs 12,500 crore. A cap on this base affects many households.
- Court Pressure: The bench cited a saline drip sold for Rs 270 that cost about Rs 11, and a cardiac stent costing about Rs 5,000 sold above Rs 25,000. It asked why only cancer drugs are covered.
- Access Argument: Solicitor General Tushar Mehta argued that margins cannot be capped beyond a limit because higher margins help medicines reach remote areas. The Court gave the government time to work out how to cap prices.
- Channel Differences: The Department of Pharmaceuticals said prices vary by whether drugs are bought from retail, hospital or online pharmacies. An expert committee under the Directorate General of Health Services will finalise the list.
Key Implications
Positive/Pros/Merits
- Lower Out-of-Pocket Costs: The Authority expects maximum retail price reductions of 20 to 70 per cent. Savings of about Rs 2,500 crore a year would reach patients directly.
- Tested Tool: In February 2019 the Authority capped the trade margin at 30 per cent on 42 non-scheduled anti-cancer drugs, effective 8 March 2019. It reportedly saved Rs 984 crore across 526 brands.
- Judicial Push: The Supreme Court's questions on other medicines create pressure for a wider rationalisation of margins.
Negative/Cons/Demerits
- Incomplete Coverage: The covered list is not final, and the effective date has not been stated. Patients do not yet see lower prices.
- Narrow Scope: The cap covers anti-cancer drugs only. The Court pointed to price gaps in saline, stents and antibiotics, which remain outside it.
- Supply Risk: The Solicitor General's argument that margins support reach to remote areas shows a risk that retailers may stock fewer items. This is the government's stated concern and it is untested.
- Past Criticism: In 2019, health groups said a trade margin cap alone would not lower prices meaningfully because maximum retail prices were already high. They wanted a cap on the maximum selling price.
Key Initiatives
- Drugs (Prices Control) Order, 2013, Paragraph 19: The government invoked this extraordinary-powers provision to cap the trade margin on anti-cancer drugs at 30 per cent of the maximum retail price.
- National Pharmaceutical Pricing Authority, 8 October 2026: At its 151st meeting it approved the cap in principle, citing that "consumer interest must remain paramount".
- Department of Pharmaceuticals: It directed the Authority to pursue trade margin rationalisation for non-scheduled anti-cancer medicines, with an expert committee due to report by 14 October 2026.
- National Pharmaceutical Pricing Authority, 28 February 2019: It capped the trade margin at 30 per cent on 42 anti-cancer drugs, effective 8 March 2019.
The Centre told the Supreme Court on 12 October 2026 that it will cap the trade margin on anti-cancer drugs at 30 per cent and expects savings of about Rs 2,500 crore a year. An expert committee under the Directorate General of Health Services is to finalise the list of medicines. The Court has given the government time to work out how to cap medicine prices more widely.
Director's Perspective
Way Forward
- Publish the final list and the effective date quickly, so the 30 per cent cap reaches patients without delay.
- Cap the maximum retail price as well as the trade margin, since health groups have said the margin cap alone may not cut prices enough.
- Extend margin rationalisation in stages to other high-markup medicines, starting with those the Court named.
- Monitor stocking in remote districts for a year, to test the claim that lower margins reduce reach.
The cap is a sound but partial step. It targets documented markups of up to 700 per cent, uses a power the government has used before, and answers a clear public-interest need. Its weakness is that the list, the date and the wider medicines question remain open, and the Court has noticed. In a Mains answer, credit price regulation under Paragraph 19, then conclude that affordable healthcare needs margin caps backed by transparent data, wider coverage and monitoring of supply.
GS Relevance
Frequently Asked Questions
What did the Centre decide on cancer drug prices on 12 October 2026?
The Centre told the Supreme Court that it will cap the trade margin on anti-cancer drugs at 30 per cent of the maximum retail price. It expects savings of about Rs 2,500 crore a year, and the covered list is still being finalised by an expert committee.
What is Paragraph 19 of the Drugs (Prices Control) Order, 2013?
Paragraph 19 is the extraordinary-powers provision of the Drugs (Prices Control) Order, 2013. The government used it in February 2019 to cap trade margins on 42 anti-cancer drugs and has invoked it again in 2026 for a 30 per cent cap on trade margin.
What did the Supreme Court say about medicine prices?
A bench of Justices Vikram Nath and Sandeep Mehta said there is hardly anything to be happy about, citing a saline drip sold for Rs 270 that cost about Rs 11. It asked why margins on other medicines cannot be capped and listed the matter for 27 October 2026.
PYQ Practice — Statement Analysis
1 Trade margin is the difference between the price at which a manufacturer sells to the trade and the maximum retail price.
The 30 per cent cap in 2026 applies to the maximum retail price of anti-cancer drugs.
2 The National Pharmaceutical Pricing Authority approved the cancer drug margin cap in principle at its 151st meeting on 8 October 2026.
The covered list of medicines is still to be finalised.
3 Paragraph 19 of the Drugs (Prices Control) Order, 2013 allows price control only for scheduled drugs.
It lets the government control prices of non-scheduled drugs too, in the public interest.